Brentuximab vedotin related bilateral Purtscher-like retinopathy unresponsive to pulse steroid therapy and intravitreal aflibercept injection
We describe a 36-year-old woman with a relapsing Hodgkin’s lymphoma who developed a severe bilateral sudden visual loss almost three weeks after the initiation of brentuximab therapy. Ancillary fundus tests yielded bilateral severe retinal arteriolar occlusion 360° and serous macular retinal detachm...
Main Authors: | Ayhan, Ziya, Kaya, Sureyya Yigit, Ozcan, Mehmet Ali, Saatci, Ali Osman |
---|---|
Format: | Article |
Language: | English |
Published: |
German Medical Science GMS Publishing House
2017-12-01
|
Series: | GMS Ophthalmology Cases |
Subjects: | |
Online Access: | http://www.egms.de/static/en/journals/oc/2017-7/oc000080.shtml |
Similar Items
-
Brentuximab vedotin in the treatment of relapsed and refractory forms of Hodgkin lymphoma
by: E A Demina
Published: (2016-06-01) -
Brentuximab vedotin is the first target drug in the treatment of hodgkin lymphoma
by: G. S. Tumyan
Published: (2018-11-01) -
TARGETED THERAPY WITH BRENTUXIMAB VEDOTIN IN RELAPSED AND REFRACTORY FORMS OF CLASSICAL HODGKIN LYMPHOMA
by: E. A. Demina
Published: (2017-11-01) -
A case of metachronous peripheral T‐Cell non‐Hodgkin lymphoma following chemotherapy for Hodgkin disease successfully treated with brentuximab vedotin
by: Federico Meconi, et al.
Published: (2020-08-01) -
Safe prolonged use of brentuximab vedotin in a patient with Classical Hodgkin Lymphoma on hemodialysis
by: Aimee Schad, et al.
Published: (2023-09-01)